Literature DB >> 11788897

Cellular sensitivity determinants to docetaxel in human gastrointestinal cancers.

Ji Seon Park1, Wataru Yamamoto, Takashi Sekikawa, Masaaki Matsukawa, Ryo Okamoto, Masao Sasaki, Kei Ukon, Keiji Tanimoto, Tsutomu Kumazaki, Masahiko Nishiyama.   

Abstract

beta-tubulin (beta-TUB), Bcl-XL, and additionally glutathione S-transferase pi (GSTpi) were found to participate in sensitivity to docetaxel (TXT) in 7 human gastrointestinal cancer cell lines. The gene expression level of beta-TUB, Bcl-XL, and GSTpi was closely correlated with the IC50 for TXT. beta-TUB amount related to TXT resistance, and GST activity was correlated with IC50 for TXT in the 30-min treatment setting. Bcl-XL transfection increased TXT resistance of COLO201 cells, whereas GST inhibition by ethacrynic acid enhanced TXT cytotoxicity. Continuous TXT treatment increased beta-TUB and GSTpi expression, but the increased GSTpi mRNA was observed in TXT-resistant HCC-48 cells alone.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11788897

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  6 in total

1.  Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines.

Authors:  Julie Scott; Robert T Dorr; Betty Samulitis; Terry H Landowski
Journal:  Cancer Chemother Pharmacol       Date:  2007-02-28       Impact factor: 3.333

2.  A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer.

Authors:  Stacy Moulder; Navneet Dhillon; Chaan Ng; David Hong; Jennifer Wheler; Aung Naing; Susan Tse; Amy La Paglia; Robert Dorr; Evan Hersh; Michelle Boytim; Razelle Kurzrock
Journal:  Invest New Drugs       Date:  2009-06-06       Impact factor: 3.850

3.  Future prospects of personalized chemotherapy in gastric cancer patients: results of a prospective randomized pilot study.

Authors:  Kazuhiro Yoshida; Kazuaki Tanabe; Hideaki Ueno; Kouji Ohta; Jun Hihara; Tetsuya Toge; Masahiko Nishiyama
Journal:  Gastric Cancer       Date:  2003       Impact factor: 7.370

Review 4.  Challenge for a better combination with basic evidence.

Authors:  Kazuhiro Yoshida; Kazuya Yamaguchi; Shinji Osada; Yoshihiro Kawaguchi; Takao Takahashi; Fumio Sakashita; Yoshihiro Tanaka
Journal:  Int J Clin Oncol       Date:  2008-06-14       Impact factor: 3.402

5.  Heterogeneity of radiation response in mesenchymal subtype glioblastoma: molecular profiling and reactive oxygen species generation.

Authors:  Christopher P Cifarelli; Angelica Jacques; Andrey Bobko
Journal:  J Neurooncol       Date:  2021-02-10       Impact factor: 4.130

6.  GSTM1 polymorphism in Oncotype DX assay is a potential predictive factor for taxane-based neoadjuvant chemotherapy in estrogen receptor-positive Chinese breast cancer patients.

Authors:  Guochun Zhang; Xueke Qian; Chongyang Ren; Lingzhu Wen; Haitong Lyu; Ning Liao
Journal:  Transl Cancer Res       Date:  2019-04       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.